166 related articles for article (PubMed ID: 18596394)
1. Improved outcome for children with acute lymphoblastic leukemia after risk-adjusted intensive therapy: a single-institution experience.
Al-Nasser A; El-Solh H; De Vol E; El-Hassan I; Alzahrani A; Al-Sudairy R; Al-Mahr M; Al-Musa A; Al-Jefri A; Saleh M; Rifai S; Belgaumi A; Osman L; Ashraf K; Salim M; Silo A; Roberts G
Ann Saudi Med; 2008; 28(4):251-9. PubMed ID: 18596394
[TBL] [Abstract][Full Text] [Related]
2. Treatment of occult or late overt testicular relapse in children with acute lymphoblastic leukemia: a Pediatric Oncology Group study.
Wofford MM; Smith SD; Shuster JJ; Johnson W; Buchanan GR; Wharam MD; Ritchey AK; Rosen D; Haggard ME; Golembe BL
J Clin Oncol; 1992 Apr; 10(4):624-30. PubMed ID: 1548525
[TBL] [Abstract][Full Text] [Related]
3. Long-term results of the pediatric oncology group studies for childhood acute lymphoblastic leukemia 1984-2001: a report from the children's oncology group.
Salzer WL; Devidas M; Carroll WL; Winick N; Pullen J; Hunger SP; Camitta BA
Leukemia; 2010 Feb; 24(2):355-70. PubMed ID: 20016527
[TBL] [Abstract][Full Text] [Related]
4. Treatment of childhood acute lymphoblastic leukemia. Long-term results of the AIEOP-ALL 87 study.
Paolucci G; Vecchi V; Favre C; Miniero R; Madon E; Pession A; Rondelli R; De Rossi G; Lo Nigro L; Porta F; Santoro N; Indolfi P; Basso G; Conter V; Aricò M;
Haematologica; 2001 May; 86(5):478-84. PubMed ID: 11410410
[TBL] [Abstract][Full Text] [Related]
5. Extended intrathecal methotrexate may replace cranial irradiation for prevention of CNS relapse in children with intermediate-risk acute lymphoblastic leukemia treated with Berlin-Frankfurt-Münster-based intensive chemotherapy. The Associazione Italiana di Ematologia ed Oncologia Pediatrica.
Conter V; Aricò M; Valsecchi MG; Rizzari C; Testi AM; Messina C; Mori PG; Miniero R; Colella R; Basso G
J Clin Oncol; 1995 Oct; 13(10):2497-502. PubMed ID: 7595699
[TBL] [Abstract][Full Text] [Related]
6. Prevention of CNS disease in intermediate-risk acute lymphoblastic leukemia: comparison of cranial radiation and intrathecal methotrexate and the importance of systemic therapy: a Childrens Cancer Group report.
Tubergen DG; Gilchrist GS; O'Brien RT; Coccia PF; Sather HN; Waskerwitz MJ; Hammond GD
J Clin Oncol; 1993 Mar; 11(3):520-6. PubMed ID: 8445427
[TBL] [Abstract][Full Text] [Related]
7. Treatment of CNS relapse in children with acute lymphoblastic leukemia: A Pediatric Oncology Group study.
Winick NJ; Smith SD; Shuster J; Lauer S; Wharam MD; Land V; Buchanan G; Rivera G
J Clin Oncol; 1993 Feb; 11(2):271-8. PubMed ID: 8426204
[TBL] [Abstract][Full Text] [Related]
8. Acute lymphoblastic leukemia in a developing country: preliminary results of a nonrandomized clinical trial in El Salvador.
Bonilla M; Moreno N; Marina N; deReyes G; Shurtleff SA; Downing JR; Behm FG; Harrison PL; Ribeiro RC; Peña O; Crist WM; Antillon FG
J Pediatr Hematol Oncol; 2000; 22(6):495-501. PubMed ID: 11132215
[TBL] [Abstract][Full Text] [Related]
9. Risk-directed therapy for childhood acute lymphoblastic leukemia. Results of the Associazione Italiana Ematologia Oncologia Pediatrica '82 studies.
Vecchi V; Aricò M; Basso G; Ceci A; Madon E; Mandelli F; Masera G; Massimo L; Pession A; Zanesco L
Cancer; 1993 Oct; 72(8):2517-24. PubMed ID: 8402470
[TBL] [Abstract][Full Text] [Related]
10. [Treatment of childhood acute lymphoblastic leukemia: randomized trials of protocols CCLSG-L 841 and I 841. (Phase III study). Children's Cancer and Leukemia Study Group].
Rinsho Ketsueki; 1989 Jul; 30(7):967-74. PubMed ID: 2681882
[TBL] [Abstract][Full Text] [Related]
11. Intensive alternating drug pairs for treatment of high-risk childhood acute lymphoblastic leukemia. A Pediatric Oncology Group pilot study.
Lauer SJ; Camitta BM; Leventhal BG; Mahoney DH; Shuster JJ; Adair S; Casper JT; Civin CI; Graham M; Kiefer G
Cancer; 1993 May; 71(9):2854-61. PubMed ID: 8467463
[TBL] [Abstract][Full Text] [Related]
12. A comparison of early intensive methotrexate/mercaptopurine with early intensive alternating combination chemotherapy for high-risk B-precursor acute lymphoblastic leukemia: a Pediatric Oncology Group phase III randomized trial.
Lauer SJ; Shuster JJ; Mahoney DH; Winick N; Toledano S; Munoz L; Kiefer G; Pullen JD; Steuber CP; Camitta BM
Leukemia; 2001 Jul; 15(7):1038-45. PubMed ID: 11455971
[TBL] [Abstract][Full Text] [Related]
13. Improved outcome with delayed intensification for children with acute lymphoblastic leukemia and intermediate presenting features: a Childrens Cancer Group phase III trial.
Tubergen DG; Gilchrist GS; O'Brien RT; Coccia PF; Sather HN; Waskerwitz MJ; Hammond GD
J Clin Oncol; 1993 Mar; 11(3):527-37. PubMed ID: 8445428
[TBL] [Abstract][Full Text] [Related]
14. Randomized assessment of delayed intensification and two methods for parenteral methotrexate delivery in childhood B-ALL: Children's Oncology Group Studies P9904 and P9905.
Winick N; Martin PL; Devidas M; Shuster J; Borowitz MJ; Paul Bowman W; Larsen E; Pullen J; Carroll A; Willman C; Hunger SP; Carroll WL; Camitta BM
Leukemia; 2020 Apr; 34(4):1006-1016. PubMed ID: 31728054
[TBL] [Abstract][Full Text] [Related]
15. Unexpected acute neurologic toxicity in the treatment of children with acute lymphoblastic leukemia.
Winick NJ; Bowman WP; Kamen BA; Roach ES; Rollins N; Jacaruso D; Buchanan GR
J Natl Cancer Inst; 1992 Feb; 84(4):252-6. PubMed ID: 1734087
[TBL] [Abstract][Full Text] [Related]
16. Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial.
Millot F; Suciu S; Philippe N; Benoit Y; Mazingue F; Uyttebroeck A; Lutz P; Mechinaud F; Robert A; Boutard P; Marguerite G; Ferster A; Plouvier E; Rialland X; Behard C; Plantaz D; Dresse MF; Philippet P; Norton L; Thyss A; Dastugue N; Waterkeyn C; Vilmer E; Otten J;
J Clin Oncol; 2001 Apr; 19(7):1935-42. PubMed ID: 11283125
[TBL] [Abstract][Full Text] [Related]
17. Intensification with intermediate-dose intravenous methotrexate is effective therapy for children with lower-risk B-precursor acute lymphoblastic leukemia: A Pediatric Oncology Group study.
Mahoney DH; Shuster JJ; Nitschke R; Lauer S; Steuber CP; Camitta B
J Clin Oncol; 2000 Mar; 18(6):1285-94. PubMed ID: 10715299
[TBL] [Abstract][Full Text] [Related]
18. Intensive oral methotrexate protects against lymphoid marrow relapse in childhood B-precursor acute lymphoblastic leukemia.
Winick N; Shuster JJ; Bowman WP; Borowitz M; Farrow A; Jacaruso D; Buchanan GR; Kamen BA
J Clin Oncol; 1996 Oct; 14(10):2803-11. PubMed ID: 8874342
[TBL] [Abstract][Full Text] [Related]
19. Long-term results of the children's cancer group studies for childhood acute lymphoblastic leukemia 1983-2002: a Children's Oncology Group Report.
Gaynon PS; Angiolillo AL; Carroll WL; Nachman JB; Trigg ME; Sather HN; Hunger SP; Devidas M;
Leukemia; 2010 Feb; 24(2):285-97. PubMed ID: 20016531
[TBL] [Abstract][Full Text] [Related]
20. Management of Ontario children with acute lymphoblastic leukemia by the Dana-Farber Cancer Institute protocols.
Desai SJ; Barr RD; Andrew M; deVeber LL; Pai MK
CMAJ; 1989 Oct; 141(7):693-7. PubMed ID: 2790605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
